Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News
05/10/2023 19:53
Oct 5 (Reuters) -
Paris-based drugmaker Sanofi SASY.PA is exploring a
potential acquisition of cancer drugmaker Mirati Therapeutics
MRTX.O , Bloomberg News reported on Thursday citing people
familiar with the matter.
A Sanofi spokesperson responded to a Reuters' request saying
the company does not comment on market rumors.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi
Majumdar)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)